Brief: MyMD Pharma's Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in Preclinical Model
12/04/2022 14:33
April 12 (Reuters) - MyMD Pharmaceuticals Inc MYMD.O :
* MYMD PHARMACEUTICALS INC-
* MYMD PHARMACEUTICALS’ LEAD COMPOUND MYMD-1 DEMONSTRATES
SUPERIOR
ANTI-INFLAMMATORY EFFECTS OVER TOP-SELLING THERAPIES IN A
PIVOTAL PRECLINICAL MODEL OF RHEUMATOID ARTHRITIS
* MYMD PHARMACEUTICALS- SUBMISSION OF INVESTIGATIONAL NEW
DRUG
(IND) APPLICATION AND PROTOCOLS FOR A PHASE 2 RA STUDY PLANNED
FOR SECOND HALF OF 2022
Source text for Eikon: ID:nBw4Y382ja
Further company coverage: MYMD.O
((Reuters.Briefs@thomsonreuters.com;))